EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy


Expert Opinion on PharmacoTherapy 11(8): 1277-1293
Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy
Malaria infection during pregnancy is a major public health problem worldwide, with 50 million pregnancies exposed to the infection every year. Approximately 25,000 maternal deaths and between 75,000 and 200,000 infant deaths could be prevented each year by effective malaria control in pregnancy. Antimalarial drug treatment and prevention has been hampered by the appearance of drug resistance, which has been a particular problem in pregnancy due to the inherent safety issues. New antimalarial drugs and combinations are being studied but there is not yet sufficient information on their efficacy or, more importantly, on their safety in pregnancy. This article provides an overview of the relevance of the topic and reviews the current antimalarial drugs recommended for pregnancy, as well as the guidelines for both treatment and prevention in women living in endemic areas and for travellers. Updated information on the drugs currently used for malaria treatment and prevention in pregnancy, including new drugs under development, is provided. The gaps on efficacy and safety information for use during pregnancy are also discussed. Prevention and case management of malaria during pregnancy is based on risk-benefit criteria and poses one of the greatest challenges to current malaria control.


Accession: 052409940

PMID: 20408744

DOI: 10.1517/14656561003733599



Related references

Current antimalarial drugs recommended by the World Health Organization for the treatment and prevention of malaria. Meditsinskaia Parazitologiia i Parazitarnye Bolezni: 56-59, 2007

Antimalarial drugs combinations for malaria prevention and treatment. Medecine et Maladies Infectieuses 31(12): 693-704, 2001

Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Tropical Medicine & International Health 8(6): 488-506, 2003

Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention. Seminars in Perinatology 38(8): 523-527, 2015

Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Review of Neurotherapeutics 13(3): 251-60; Quiz 261, 2013

Treatment and prevention of malaria in pregnancy: opportunities and challenges. Expert Review of Anti-Infective Therapy 4(4): 687-702, 2006

Monitoring antimalarial drug efficacy: current challenges. Current Infectious Disease Reports 11(1): 59-65, 2008

Challenges in the development of antimalarial drugs with causal prophylactic activity. Transactions of the Royal Society of Tropical Medicine and Hygiene 92(6): 577-579, 1999

Challenges in the development of antimalarial drugs with causal prophylactic activity. Transactions of the Royal Society of Tropical Medicine and Hygiene 92(6): 577-579, 1998

Challenges in Diagnosis and Treatment of Lung Cancer in People with Intellectual Disabilities: Current State of Knowledge. Lung Cancer International 2016(): 6787648-6787648, 2016